Skip to content
DataLookout
Menu

NCT07287033

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

StatusRecruiting
PhasePhase 1
SponsorMabylon AG
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria revised
    • Enrollment increased: 48 → 56 participants
    • Secondary endpoints: details revised at 11 of 21 entries
  2. Notable Eligibility criteria expanded, about 34 words
    • Secondary endpoints: details revised at 11 of 21 entries
    • Site details revised at 4 of 9 sites
  3. Minor Trial sites expanded: 2 → 9 locationsv4
  4. Minor Study sites: 1 to 2v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary endpoint revised
    • Site details revised
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of Subjects with Adverse Events and Serious Adverse Events (Safety and Local Tolerability)
Timeframe: From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)

Secondary (21)

Pharmacokinetics: Cmax (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Pharmacokinetics: Tmax (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Pharmacokinetics: AUClast (Part A, SAD, Cohorts A1-A3)
Pharmacokinetics: AUClast (Part A, MD, Cohort A4)
Pharmacokinetics: AUC0-504hr (Part A, SAD, Cohorts A1-A3)
Show 16 moreShow less
Pharmacokinetics: AUC0-336hr (Part B, Cohorts B1-B2)
Pharmacokinetics: AUC0-336hr (Part A, MD, Cohort A4)
Pharmacokinetics: AUCinf (Part A, SAD, Cohorts A1-A3; Part B, Cohorts B1-B2)
Pharmacokinetics: AUCinf (Part A, MD, Cohort A4)
Pharmacokinetics: AUC%extrap (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Pharmacokinetics: λz (Part A, MD, Cohort A4; Part B, Cohorts B1-B2)
Pharmacokinetics: t½ (Part A, MD, Cohort A4; Part B, Cohorts B1-B2)
Pharmacokinetics: CL/F (Part A, MD; Cohort A4, Day 15; Part B, Cohorts B1-B2)
Pharmacokinetics: Vz/F (Part A, MD, Cohort A4, Day 15; Part B, Cohorts B1-B2)
Pharmacokinetics: Racc,Cmax (Part A, MD, Cohort A4)
Pharmacokinetics: Racc,C72 (Part A; MD; Cohort A4)
Pharmacokinetics: Racc,C168 (Part A, MD, Cohort A4)
Pharmacokinetics: Racc,AUC0-336hr (Part A, MD, Cohort A4)
Immunogenicity: ADA (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Immunogenicity: Treatment-enhanced ADA (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
Immunogenicity: ADA Titers (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)

Arms and interventions

Part A, Single Ascending Dose, Dose Level 1 (Healthy Volunteers)Experimental

Cohort A1: MY006 or Placebo, subcutaneous, single dose in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively.

Part A, Single Ascending Dose, Dose Level 2 (Healthy Volunteers)Experimental

Cohort A2: MY006 or Placebo, subcutaneous, single dose in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively.

Part A, Single Ascending Dose, Dose Level 3 (Healthy Volunteers)Experimental

Cohort A3: MY006 or Placebo, subcutaneous, single dose in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively.

Part A, Multiple Dose (Healthy Volunteers)Experimental

Cohort A4: MY006 or Placebo, subcutaneous, every 2 weeks, total of 2 doses in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively.

Part B, Single Dose with Early Peanut Challenge (Peanut-Allergic Patients)Experimental

Cohort B1: MY006 or Placebo, subcutaneous, single dose in adults and adolescents. Peanut challenge will occur early after dosing. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively.

Part B, Single Dose with Late Peanut Challenges (Peanut-Allergic Patients)Experimental

Cohort B2: MY006 or Placebo, subcutaneous, single dose in adults and adolescents. Peanut challenge will occur late after dosing. The cohort will consist of up to 16 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively.

Drugs: MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)

Sites

9 sites in 1 country